This week, Columbia University and Beth Israel Deaconness Medical Center researchers reported their assessment of the newly approved COVID-19 booster shot. Unfortunately, the recent release by the FDA of the newest booster shot is not improving our chances of becoming infected by the newer strains of the SARS-CoV-2 virus.
Columbia University
https://www.biorxiv.org/content/10.1101/2022.10.22.513349v1 We have seen the SARS-CoV-2 virus evade immune responses from prior vaccinations, booster shots, and natural infection. A new bivalent formulation based on the original Moderna and Pfizer mRNA and the Omicron BA.4/BA.5 variants was approved by the FDA within the past 60 days. Current research shows that the new booster shot did not induce superior neutralizing antibody responses in humans compared to the original monovalent vaccine. This is in direct contradiction to current federal statements of the booster shot’s efficacy.
The Beth Israel Deaconness Medical Center is the teaching hospital of the Harvard Medical School in Boston, Massachusetts. https://www.biorxiv.org/content/10.1101/2022.10.24.513619v1 At the time of the study, the BA.5 variant of COVID-19 was dominant. Therefore, a bivalent booster shot was developed to reduce infection and transmission of the coronavirus. However, data shows that the new booster shot is no better than previous vaccines or booster shots.
Current Treatment
https://www.cdc.gov/media/releases/2022/s1022-covid-director.html If the CDC Director, Rochelle Walensky, can be infected after taking all the precautions that the CDC has, what credibility does that give Americans about any new treatment option? I am confident that with over 130 vaccines being developed worldwide, several will successfully stop and prevent the spread of COVID-19.
However, all the cards seem to be in the early vaccine developers, Pfizer and Moderna. Early clinical tests showed that the vaccine was transitory at best – maybe offering protection for six months or more. Therefore, booster shots were quickly developed, and the efficacy of those did not last half as long as the original vaccine.
The Mouse Booster
https://justthenews.com/government/federal-agencies/eight-boosted-mice-fda-panned-omicron-jab-approval-based-irrelevant Previous clinical tests were extensive and somewhat exhaustive to determine the effective treatment to prevent the spread of the SARS-CoV-2 virus. However, the latest bivalent booster shot used eight mice as the clinical test group to develop and release the new booster shot. The Emergency Use Authorization statement did not include clinical test data relating to the mice trials rather than human trials.
Why? The CDC determined that it did not have time to wait for human trials. A COVID surge is expected, and the new booster shot was expected to be effective against the pandemic virus.
Conclusion
I was fortunate to have contracted both the Delta and Omicron variants. My immune system allowed me to weather the storm and recover quickly. Unfortunately, it appears that I probably have another date with a future variant as the coronavirus treatments available in the United States are definitely subpar with CDC expectations and media reports.
Some scientists think vaccinations and booster shots do more harm than good. It is also confusing data analysis of why hospitalizations and death rates have fallen significantly in recent months. Worldwide trends, as seen in https://www.worldometers.info/coronavirus/, show infections at the lowest levels in 15 months and the death rate at the lowest since COVID-19 statistics were reported. The survival rate worldwide is 99%.
The United States has seen similar trends regarding infections and death rates attributable to COVID-19. https://www.worldometers.info/coronavirus/country/us/ The current death rate is descending towards 200/day. However, the death rate from the pandemic virus is double digits and remains at
that level. Japan, S. Korea, Taiwan, and France have the highest daily cases rates of COVID-19 this week.
Live Longer & Enjoy Life! Red O’Laughlin RedOLaughlin.com
Your point of view caught my eye and was very interesting. Thanks. I have a question for you.